about
Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma.Supportive care in patients with advanced non-small-cell lung cancer.Advanced chondrosarcomas: role of chemotherapy and survival.Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?Treating soft tissue sarcomas with adjuvant chemotherapy.Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.Angiosarcomas and other sarcomas of endothelial origin.GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer.Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors.Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.[Focus on GIST management].Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications.Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study.Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the eldLong-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinibRandomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma GPrimary adrenal angiosarcoma and functioning adrenocortical adenoma: an exceptional combined tumorDevelopment and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinibMalignant peripheral nerve sheath tumorsAdvanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapyImatimid-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases[Large mediastinal mass of heterotopic thyroid tissue: a case report and review of literature]
P50
Q33393740-D0A336C4-11EF-4169-9D40-A07C62B619F4Q35345665-761D8C58-8E83-493E-BD23-76D9BE586E27Q36648391-D3BD67ED-B159-473B-9B04-53923493FF3FQ37265042-82BF5965-A696-4C5E-B57F-E1C60CEA19A4Q37622856-C3AF6810-3F92-4B8D-9F90-D4DE3CE8D4CAQ37850703-4A967526-19FD-44A9-9276-23C0889B384FQ37969213-C53ECFBF-7E8F-4D39-AF47-63779F049CB0Q38149142-BE0FBE8C-5825-4408-A31F-E7B73BC854A4Q38445737-DCD34C27-1195-4C5D-94D8-45C9EFDC6C70Q41737244-8622A560-7996-4764-A3A6-6FAE6FBFE9C1Q42877987-A361D55A-2821-400E-A07F-FE7ADFD49199Q43059684-4548E726-3EAF-4990-9BF5-1040EB8C9B7DQ43138491-832DEBB4-8F39-4667-9D34-7B1F6BB242B6Q43932267-A969E20E-BAEC-4D90-B613-842B4ACF4891Q44487114-144E805B-F647-4B1B-96CF-7CCC05F91577Q45180255-249A884F-2973-4ECB-AC52-485AC4F8A788Q46726889-AE01AD0C-124B-474F-AAA6-E0AF84189918Q48283622-6AEBE473-AB23-403E-A9D5-9B0C6E0DCBAAQ51066747-93D420AB-0B43-43F0-A8BA-54976AC4341DQ52750601-C7A8A7DD-5603-4826-A06D-230EBA4E3B4BQ53217895-C08E4F80-D4ED-4843-B71C-BB481E275744Q57570884-65D24614-7FD5-464A-B812-A54181366C66Q57570892-C41A3DCC-7F14-49D2-B1D3-2454A2654CF9Q57817500-64E4388A-9805-438A-BA59-6D63E98D9175Q59586301-FF01E78F-18B8-49DA-B045-C35E000F954CQ60021423-61113F61-0A36-46D5-9AD5-53058B0E96EDQ60021512-E9B47842-256D-47DB-81AD-58449796CEA9Q60690544-73E0952D-E9CD-4818-B6B1-C50DF3057FE9Q81129501-94453BFB-D862-448E-8E8D-7565BA7D5494
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Angela Cioffi
@ast
Angela Cioffi
@en
Angela Cioffi
@es
Angela Cioffi
@nl
type
label
Angela Cioffi
@ast
Angela Cioffi
@en
Angela Cioffi
@es
Angela Cioffi
@nl
prefLabel
Angela Cioffi
@ast
Angela Cioffi
@en
Angela Cioffi
@es
Angela Cioffi
@nl
P108
P1053
Q-4622-2016
P106
P1153
14024172500
P21
P31
P3829
P496
0000-0001-8290-6815